Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Fady G
FG
Haddad
Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.|Oncology Department, Bordet Institute, Brussels, Belgium.
Hampig R
HR
Kourie
Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Joseph
J
Kattan
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D058990:Molecular Targeted Therapy; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
EGFR; T790M; non-small-cell lung cancer